CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.040
0.00 (0.00%)
At close: Nov 13, 2026, 4:00 PM EST
2.040
0.00 (0.00%)
Pre-market: Nov 16, 2026, 4:03 AM EST

CytomX Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
14.0376.2138.1101.2153.1637.31
Revenue Growth
-87.66%-44.82%36.45%90.38%42.48%-45.47%
Gross Profit
14.0376.2138.1101.2153.1637.31
Selling, General & Admin
34.3628.7429.7330.0240.4539.16
Research & Development
74.5567.0383.3877.68106.55114.19
Operating Expenses
108.9295.77113.11107.7147153.35
Operating Income
-94.89-19.5625-6.48-93.84-116.04
Interest & Investment Income
9.45.217.149.841.680.26
Currency Exchange Gain (Loss)
0.040.03-0.04-0.030.34-0.08
Other Non Operating Income (Expenses)
-0.03-----
EBT Excluding Unusual Items
-85.48-14.3332.093.32-91.82-115.87
Merger & Restructuring Charges
--2.8---7.5-
Pretax Income
-85.19-17.1332.093.32-99.32-115.87
Income Tax Expense
0.230.240.223.89--
Net Income
-85.42-17.3731.87-0.57-99.32-115.87
Preferred Dividends & Other Adjustments
33----
Net Income to Common
-88.42-20.3731.87-0.57-99.32-115.87
Net Income Growth
------
Shares Outstanding (Basic)
19613884746664
Shares Outstanding (Diluted)
19613885746664
Shares Change
66.32%62.77%14.82%12.27%2.48%39.01%
EPS (Basic)
-0.45-0.150.38-0.01-1.51-1.81
EPS (Diluted)
-0.45-0.150.38-0.01-1.51-1.81
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-51-75.81-86.54-56.88-112.53-120.64
Free Cash Flow Per Share
-0.26-0.55-1.02-0.77-1.71-1.88
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-676.41%-25.67%18.10%-6.41%-176.50%-311.00%
Profit Margin
-630.34%-26.73%23.08%-0.56%-186.82%-310.54%
Free Cash Flow Margin
-363.57%-99.48%-62.66%-56.19%-211.67%-323.33%
EBITDA
-93.66-18.1926.76-4.31-91.39-113.34
EBITDA Margin
--23.87%19.38%-4.26%-171.91%-
D&A For EBITDA
1.221.381.772.182.442.71
EBIT
-94.89-19.5625-6.48-93.84-116.04
EBIT Margin
--25.67%18.10%-6.41%-176.50%-
Effective Tax Rate
--0.70%117.12%--
SEC Filings: 10-K · 10-Q